# Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

> **NCT02995772** · PHASE3 · COMPLETED · sponsor: **Dharmais National Cancer Center Hospital** · enrollment: 122 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Aromatase Inhibitors (Arimidex)
- **DRUG:** Tamoxifen
- **PROCEDURE:** SOB
- **DRUG:** FAC
- **DRUG:** Aromatase Inhibitors (Femara)
- **DRUG:** Aromatase Inhibitors (Aromasin)

## Key facts

- **NCT ID:** NCT02995772
- **Lead sponsor:** Dharmais National Cancer Center Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02995772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02995772, "Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02995772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*